Connor Clark & Lunn Investment Management Ltd. Raises Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Connor Clark & Lunn Investment Management Ltd. grew its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 114.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,949 shares of the specialty pharmaceutical company’s stock after buying an additional 12,245 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.05% of KalVista Pharmaceuticals worth $266,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Great Point Partners LLC bought a new position in KalVista Pharmaceuticals during the 2nd quarter worth approximately $15,768,000. Emerald Advisers LLC boosted its holdings in KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after acquiring an additional 192,091 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of KalVista Pharmaceuticals by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in KalVista Pharmaceuticals by 4.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 944 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC lifted its holdings in KalVista Pharmaceuticals by 323.5% in the second quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company’s stock worth $807,000 after buying an additional 52,347 shares during the period.

KalVista Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:KALV opened at $10.06 on Monday. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.39 and a 52-week high of $16.88. The business’s 50 day moving average is $10.95 and its 200 day moving average is $11.90. The stock has a market cap of $434.79 million, a P/E ratio of -2.85 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. On average, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Needham & Company LLC reissued a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,352 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the sale, the chief executive officer now owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. This trade represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,016 shares of company stock worth $319,344 in the last ninety days. 10.50% of the stock is owned by insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).